Skip to main content

Table 3 Rate of response after 3 and 5 months, n (%)

From: Omalizumab for chronic urticaria in Latin America

Time (months)

No. of patients

Complete response

Partial response

Non-response

3

9

3 (33.3)

4 (44.4)

2 (22.2)

5

4

3 (75.0)

0 (0.0)

1 (25.0)